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Dear colleagues,
With keen interest, we read your recent editorial contem-
plating the important question, What the main driving force
for innovation in orthopaedics is? We feel that some key
questions should be discussed in detail:
Is it really for the sake of the patient when the
industry, aiming for an increase of market shares and
sales puts out new developments of products every
2–3 years? What is the role of consultant payments to
key opinion leaders with regards to widespread
introduction of innovative products? How can we
make sure that new developments are better or at
least equal to well proven ones? How to measure the
benefit for the patient? Should we increase the
administrative and reporting hurdles for innovations?
As researchers and orthopaedic surgeons, we sometimes
tend to see the glass half-full rather than half-empty when it
comes to innovations. As member of the developing group
of an innovative product, we have committed ourselves to a
new idea, believe in the benefit for our patients and hence are
keen to promote it. By promoting a novel development, one
may nationally and internationally get more recognized.
One needs to be very self-critical here not to forget the initial
driving force. It should be improvement of patient’s care, not
personal benefits, which may come along with it.
Do we need an ethical codex for working together with
industry partners on the development and promotion of
innovations? Two worlds, the medical and the industry
world, are in some ways diametrically opposed. On the
other hand, these two worlds need each other. It is a very
thin line we walk between these two worlds when we work
together with industry partners to develop new techniques
or implants. Usually, the industry does not come up with
ideas making their life more difficult. It is we, the ortho-
paedic surgeons, who should define rules of cooperation
with industry partners. Should these also include a pathway
for introduction of novel products to our patients? What
kind of research has to be performed to use it in our
patients: computer simulation, mechanical testing, animal
studies, cadaver studies, pilot studies?
In your editorial, several examples were given in which
the industry had pushed a product strongly into the market
which turned out to be not beneficial or even harmful to the
patient, like failing artificial ligaments, metal on metal hip
implants and others.
In some medical innovations, the product, the idea or
surgical concept itself is not the problem, but when intro-
duced to less-experienced surgeons, the problem starts.
Unfortunately, the industry keeps on recommending and
promoting it to every orthopaedic surgeon, as their main
goal is to increase the volume of sales. As a typical
example, which was not mentioned in the editorial, double-
bundle ACL reconstruction can be considered. We learnt
from recent well-performed biomechanical as well as
clinical studies that a well-performed double-bundle ACL
might result in slightly superior outcomes, for the price of
an important increase in surgical complexity. In expert
hands, there is no problem. Others might struggle. A
solution might be to introduce new techniques on a ‘‘no
train–no use’’ policy, giving innovators the chance to pass
on in-depth knowledge from designer to user.
Even then there is no guarantee that we will not do harm to
our patients when we set foot on new and uncharted territory.
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